Partner Winston Kirton and Counsel Payal Cramer authored an alert that has been republished in LexisNexis Practical Guidance. Titled “FDA Issues Draft Guidance on Diversity Action Plans,” the alert outlines some of the key points regarding Diversity Action Plans for clinical studies, as well as the reasoning behind the new measures.
Read the article. (subscription required)